Antidepressant-relevant concentrations of the ketamine metabolite (2 R ,6 R )-hydroxynorketamine do not block NMDA receptor function
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Significance: Standard antidepressant treatments require weeks to show effectiveness. A single subanesthetic dose of ketamine rapidly attenuates many clinical signs and symptoms of depression; however, ketamine treatment also has many adverse effects, including dissociation and potential for abuse, which are mediated by NMDA glutamate receptor (NMDAR) inhibition. Previous work has revealed that the ketamine metabolite (2 R ,6 R )-hydroxynorketamine (HNK) induces antidepressant-like responses in rodents while minimizing the adverse effects observed with ketamine. The results of this study, using a multitude of experimental approaches, confirm that antidepressant-relevant concentrations of (2 R ,6 R )-HNK are not sufficient to block NMDARs. This provides a basis for work directed at alternative molecular targets and toward novel drugs that exert rapid antidepressant effects independent of NMDAR inhibition and NMDAR-mediated adverse effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“recent research suggests that (R)-ketamine and the ketamine metabolite (2R,6R)-HNK may exert antidepressant-like effects by upregulating AMPAR transmission independent of NMDAR antagonism [30,31].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [31]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“peak levels of (2R,6R)-HNK in the mouse hippocampus were 7.57 ± 2.13 μM 10 minutes following systemic administration of a dose (10 mg/kg i.p.) that results in antidepressant-like effects in several behavioral tests and returned to near baseline levels by two hours post-administration.”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lumsden et al., 2019
The cited source says what the claim attributes to it.
In the citing paper
“NMDAR blockade does not explain the mechanism of action of (2R,6R)-HNK as its affinity for and functional effects at NMDARs are beyond therapeutically relevant concentrations (Lumsden et al., 2019).”
From Mechanisms of ketamine and its metabolites as antidepressants (2022) · cites this paper as Lumsden et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 3×
“Although there are a multitude of treatment options for depression, typical pharmacotherapies require daily administration over multiple weeks before improvement is expected, with many patients failing to find an effective therapy (3).”
BackgroundInfluentialAntidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“Demethylation of the methyl amine on ketamine ’ s central cyclohexyl ring generates the nor-ketamines, which are then hydroxylated on the 4, 5, or 6 position of the cyclohexyl ring to form the HNKs.”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766 · cited 1×
“Furthermore, ketamine is effective in patients who are refractory to typical antidepressants (4 – 9).”
BackgroundSelf-citationKrystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Although ketamine is a promising alternative to standard clinically used antidepressants, it induces adverse effects at antidepressant doses, particularly dissociation (10).”
BackgroundmTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 2×
“In addition, the possibility cannot be ruled out that immediate changes in mBDNF and mTOR activation occur in a narrow time window following a treatment (34, 35) and may, therefore, have been missed in the earlier study.”
BackgroundResultNMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 2×
“In addition, the possibility cannot be ruled out that immediate changes in mBDNF and mTOR activation occur in a narrow time window following a treatment (34, 35) and may, therefore, have been missed in the earlier study.”
BackgroundResultThe anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist.
Wong, E. H., Kemp, J. A., Priestley, T., Knight, A. R., Woodruff, G. N., & Iversen, L. L. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.18.7104 · Cited by 1,819 · cited 1×
“Each electrophysiological experiment in this study supported an NMDAR inhibition rank order of ketamine > (2S,6S)-HNK > (2R,6R)-HNK, a conclusion in agreement with the published inhibitory constants (Ki) for ketamine, (2S,6S)-HNK, and (2R,6R)HNK of <5, 10–20, and >100 μM respectively, to displace [(3)H]MK801 binding t…”
NMDAR inhibition-independent antidepressant actions of ketamine metabolites
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2016) · Nature · doi:10.1038/nature17998 · Cited by 1,609 · cited 10×
“(2S,6S)-HNK was also identified as a potential antidepressant, but with lower potency than (2R,6R)-HNK (14).”
BackgroundResultInfluentialSelf-citationKetamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260 · cited 21×
“These findings support the hypothesis that direct inhibition of NMDARs by (2 R ,6 R )- HNK is not a determinant of the antidepressant-relevant effects of this ketamine metabolite.”
BackgroundInfluentialSelf-citationMurrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez, A. M., Iqbal, S., Pillemer, S., Foulkes, A., Shah, A., et al. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13030392 · Cited by 1,205
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife, S., Kammerer, W. A., Quezado, Z., Luckenbaugh, D. A., Salvadore, G., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.90 · Cited by 963
Self-citationMorgan, C. J. A., Curran, H. V., & the Independent Scientific Committee on Drugs (ISCD) (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03576.x · Cited by 667 · cited 1×
“Furthermore, ketamine, a derivative of the illicit drug phencyclidine, is widely abused (11).”
BackgroundDiazGranados, N., Ibrahim, L. A., Brutsche, N. E., Ameli, R., Henter, I. D., Luckenbaugh, D. A., Machado-Vieira, R., & Zarate, C. A. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05327blu · Cited by 564
Self-citationDomino, E. F., & Warner, D. S. (2010) · Anesthesiology · doi:10.1097/aln.0b013e3181ed09a2 · Cited by 520
[3H]MK‐801 Labels a Site on the N‐Methyl‐D‐Aspartate Receptor Channel Complex in Rat Brain Membranes
Wong, E. H. F., Knight, A. R., & Woodruff, G. N. (1988) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1988.tb13260.x · Cited by 454 · cited 1×
“Each electrophysiological experiment in this study supported an NMDAR inhibition rank order of ketamine > (2S,6S)-HNK > (2R,6R)-HNK, a conclusion in agreement with the published inhibitory constants (Ki) for ketamine, (2S,6S)-HNK, and (2R,6R)HNK of <5, 10–20, and >100 μM respectively, to displace [(3)H]MK801 binding t…”
Tricklebank, M. D., Singh, L., Oles, R. J., Preston, C., & Iversen, S. D. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90754-1 · Cited by 433
Zarate, C. A., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L. V., Ramamoorthy, A., Moaddel, R., & Wainer, I. W. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.004 · Cited by 282 · cited 1×
“1), are the major HNK metabolites found in human plasma and in rodent plasma and brain (13 – 15).”
BackgroundSelf-citationMg2+Imparts NMDA Receptor Subtype Selectivity to the Alzheimer's Drug Memantine
Kotermanski, S. E., & Johnson, J. W. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.3703-08.2009 · Cited by 271
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., & Zarate, C. A. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.105 · Cited by 271
Self-citationFukumoto, K., Fogaça, M. V., Liu, R.-J., Duman, C., Kato, T., Li, X.-Y., & Duman, R. S. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1814709116 · Cited by 188 · cited 3×
“This is in line with previous studies reporting antidepressant-related behavioral effects of (2R,6R)-HNK similar to those of ketamine in mice and rats (14, 20, 27, 28).”
BackgroundResultSubunit-specific mechanisms and proton sensitivity of NMDA receptor channel block
Dravid, S. M., Erreger, K., Yuan, H., Nicholson, K., Le, P., Lyuboslavsky, P., Almonte, A., Murray, E., Mosley, C., Barber, J., et al. (2007) · The Journal of Physiology · doi:10.1113/jphysiol.2006.124958 · Cited by 184 · cited 2×
“, 10 μM, as previously determined (14)], in the nominal absence of extracellular Mg, the activity of GluN1/GluN2A, GluN1/GluN2B, GluN1/ GluN2C, and GluN1/GluN2D receptors was inhibited by >50% (39).”
BackgroundResultSelf-citationIdentifying fast-onset antidepressants using rodent models
Ramaker, M. J., & Dulawa, S. C. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.36 · Cited by 182 · cited 1×
“This hyponeophagic response time is decreased by antidepressant drugs (33).”
BackgroundEffects of a ketamine metabolite on synaptic NMDAR function
Suzuki, K., Nosyreva, E., Hunt, K. W., Kavalali, E. T., & Monteggia, L. M. (2017) · Nature · doi:10.1038/nature22084 · Cited by 180 · cited 2×
“It has been debated, however, whether NMDAR inhibition, the mechanism proposed to underlie the antidepressant effects of ketamine, contributes to the antidepressant effects of (2R,6R)-HNK (14, 31, 32, 40).”
BackgroundMoaddel, R., Abdrakhmanova, G., Kozak, J., Jozwiak, K., Toll, L., Jimenez, L., Rosenberg, A., Tran, T., Xiao, Y., Zarate, C. A., et al. (2013) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2012.11.023 · Cited by 176 · cited 1×
“Each electrophysiological experiment in this study supported an NMDAR inhibition rank order of ketamine > (2S,6S)-HNK > (2R,6R)-HNK, a conclusion in agreement with the published inhibitory constants (Ki) for ketamine, (2S,6S)-HNK, and (2R,6R)HNK of <5, 10–20, and >100 μM respectively, to displace [(3)H]MK801 binding t…”
Self-citationKetamine: new uses for an old drug?
Hirota, K., & Lambert, D. G. (2011) · British Journal of Anaesthesia · doi:10.1093/bja/aer221 · Cited by 162
Yang, C., Qu, Y., Abe, M., Nozawa, D., Chaki, S., & Hashimoto, K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.12.020 · Cited by 162 · cited 1×
“We note one research group has reported being unable to detect antidepressant-relevant behavioral effects of (2R,6R)-HNK in rodent behavioral tests (41, 42).”
BackgroundCavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Leung, L. Y., & Baillie, T. A. (1986) · Journal of Medicinal Chemistry · doi:10.1021/jm00161a043 · Cited by 135 · cited 1×
“Earlier studies in rodents found that ketamine and norketamine exert anesthetic effects, but (2S,6S;2R,6R)-HNK does not (16).”
BackgroundPham, T. H., Defaix, C., Xu, X., Deng, S.-X., Fabresse, N., Alvarez, J.-C., Landry, D. W., Brachman, R. A., Denny, C. A., & Gardier, A. M. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.10.020 · Cited by 131
NMDAR-independent, cAMP-dependent antidepressant actions of ketamine
Wray, N. H., Schappi, J. M., Singh, H., Senese, N. B., & Rasenick, M. M. (2019) · Molecular Psychiatry · doi:10.1038/s41380-018-0083-8 · Cited by 123
Yao, N., Skiteva, O., Zhang, X., Svenningsson, P., & Chergui, K. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.239 · Cited by 118 · cited 1×
“By 24 h after administration of 10 mg/kg (2R,6R)-HNK or ketamine to mice, induction of long-term potentiation was impaired in the nucleus accumbens and AMPAR-mediated responses were depressed in ventral tegmental area dopaminergic neurons (22).”
BackgroundShirayama, Y., & Hashimoto, K. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyx108 · Cited by 111 · cited 1×
“We note one research group has reported being unable to detect antidepressant-relevant behavioral effects of (2R,6R)-HNK in rodent behavioral tests (41, 42).”
BackgroundMoaddel, R., Venkata, S. L. V., Tanga, M. J., Bupp, J. E., Green, C. E., Iyer, L., Furimsky, A., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2010) · Talanta · doi:10.1016/j.talanta.2010.08.005 · Cited by 108
Self-citationChou, D., Peng, H.-Y., Lin, T.-B., Lai, C.-Y., Hsieh, M.-C., Wen, Y.-C., Lee, A.-S., Wang, H.-H., Yang, P.-S., Chen, G.-D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.033 · Cited by 104 · cited 2×
“Ex vivo studies revealed that antidepressant-relevant concentrations of (2R,6R)-HNK produce a robust potentiation of AMPARmediated excitatory synaptic transmission in slices from the hippocampus (14) and the midbrain ventrolateral periaqueductal gray of rats (24).”
BackgroundA study of the N-methyl-D-aspartate antagonistic properties of anticholinergic drugs
McDonough, J. H., & Shih, T. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)00372-p · Cited by 85
Synthesis and N-Methyl-d-aspartate (NMDA) Receptor Activity of Ketamine Metabolites
Morris, P. J., Moaddel, R., Zanos, P., Moore, C. E., Gould, T., Zarate, C. A., & Thomas, C. J. (2017) · Organic Letters · doi:10.1021/acs.orglett.7b02177 · Cited by 83 · cited 1×
“Each electrophysiological experiment in this study supported an NMDAR inhibition rank order of ketamine > (2S,6S)-HNK > (2R,6R)-HNK, a conclusion in agreement with the published inhibitory constants (Ki) for ketamine, (2S,6S)-HNK, and (2R,6R)HNK of <5, 10–20, and >100 μM respectively, to displace [(3)H]MK801 binding t…”
Self-citationHighland, J. N., Morris, P. J., Zanos, P., Lovett, J., Ghosh, S., Wang, A. Q., Zarate, C. A., Thomas, C. J., Moaddel, R., & Gould, T. D. (2019) · Journal of Psychopharmacology · doi:10.1177/0269881118812095 · Cited by 62 · cited 1×
“This is in line with previous studies reporting antidepressant-related behavioral effects of (2R,6R)-HNK similar to those of ketamine in mice and rats (14, 20, 27, 28).”
ResultSelf-citationHo, M.-F., Correia, C., Ingle, J. N., Kaddurah-Daouk, R., Wang, L., Kaufmann, S. H., & Weinshilboum, R. M. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.032 · Cited by 49 · cited 1×
“4 μM (25), and enhance structural plasticity in mouse mesencephalic and human induced pluripotent stem cell-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signaling at a concentration of 0.”
BackgroundA comparison of PCP-like compounds for NMDA antagonism in two models
Bennett, D. A., Bernard, P. S., & Amrick, C. L. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90083-5 · Cited by 44
Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine
De Vry, J., & Jentzsch, K. R. (2003) · Behavioural Pharmacology · doi:10.1097/00008877-200305000-00007 · Cited by 43 · cited 1×
“Specifically, noncompetitive NMDAR antagonists, including ketamine and phencyclidine (46), produce discriminative stimulus effects in drug discrimination protocols and manifest cross-drug substitution profiles at an antidepressant-relevant dose range.”
BackgroundWhat is hydroxynorketamine and what can it bring to neurotherapeutics?
Singh, N. S., Zarate, C. A., Moaddel, R., Bernier, M., & Wainer, I. W. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.971760 · Cited by 38
Self-citationCollo, G., Cavalleri, L., Chiamulera, C., & Merlo Pich, E. (2018) · NeuroReport · doi:10.1097/wnr.0000000000001131 · Cited by 37
Zanos, P., Moaddel, R., Morris, P. J., Georgiou, P., Fischell, J., Elmer, G. I., Alkondon, M., Yuan, P., Pribut, H. J., Singh, N. S., et al. (2017) · Nature · doi:10.1038/nature22085 · Cited by 34
Self-citationKavalali, E. T., & Monteggia, L. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.210 · Cited by 29 · cited 2×
“It has been debated, however, whether NMDAR inhibition, the mechanism proposed to underlie the antidepressant effects of ketamine, contributes to the antidepressant effects of (2R,6R)-HNK (14, 31, 32, 40).”
Background
Cited by
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
“Ketamine exhibits high affinity for the phencyclidine site of the N-methyl-D-aspartate receptor (NMDAR) (24, 25).”
BackgroundSelf-citationDuman, R. S., Deyama, S., & Fogaça, M. V. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14630 · Cited by 321
“Importantly, (2R,6R)-HNK has very low affinity for the NMDAR channel and does not have the side effect profile of ketamine in rodent models (Lumsden et al., 2019; Zanos et al., 2016), although there is evidence that high concentrations of (2R,6R)-HNK produce effects similar to ketamine”
BackgroundMonoamine Neurotransmitters Control Basic Emotions and Affect Major Depressive Disorders
Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., Xu, S., Wang, F., & Huang, J. H. (2022) · Pharmaceuticals · doi:10.3390/ph15101203 · Cited by 253
“Dopamine (DA) has become a synonym for joy and reward [17], thus increasing DA might be a good way for treating MDD [18,19], and, indeed, the US FDA (food and drug agency) recently approved ketamine as a drug capable of rapid antidepressant function in 2019 [20,21].”
BackgroundSelf-citationThe role of dissociation in ketamine’s antidepressant effects
Ballard, E. D., & Zarate, C. A. (2020) · Nature Communications · doi:10.1038/s41467-020-20190-4 · Cited by 220
Self-citationStructural basis of ketamine action on human NMDA receptors
Zhang, Y., Ye, F., Zhang, T., Lv, S., Zhou, L., Du, D., Lin, H., Guo, F., Luo, C., & Zhu, S. (2021) · Nature · doi:10.1038/s41586-021-03769-9 · Cited by 218
Metadata
- Authors
- Lumsden, E. W., Troppoli, T. A., Myers, S. J., Zanos, P., Aracava, Y., Kehr, J., Lovett, J., Kim, S., Wang, F.-H., Schmidt, S., Jenne, C. E., Yuan, P., Morris, P. J., Thomas, C. J., Zarate, C. A., Moaddel, R., Traynelis, S. F., Pereira, E. F. R., Thompson, S. M., Albuquerque, E. X., & Gould, T. D.
- Affiliations
- University of Maryland, Baltimore (US)
- Emory University (US)
- Department of Physiology and Pharmacology, Karolinska Institute, SE-171 77 Stockholm, Sweden;
- National Institutes of Health (US)
- Karolinska Institutet (SE)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2019-02-22
- Volume
- 116
- Issue
- 11
- Pages
- 5160-5169
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC6421428
- OpenAlex
- W2917916000
- Cited by
- 158
- References
- 46
- Citations by year
- 2026: 17 · 2025: 17 · 2024: 15 · 2023: 24 · 2022: 19 · 2021: 27 · 2020: 23 · 2019: 16
- FWCI
- 13.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Institute of Mental Health (R01MH107615, R01NS065371)
- Harrington Discovery Institute (NA)
- U.S. Department of Veterans Affairs (1I01BX004062)
- HHS | NIH | National Institute of Neurological Disorders and Stroke (R01NS065371)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Keywords
- ketamine metabolites, (2R,6R)-hydroxynorketamine, NMDA receptor, antidepressant effects, rapid-acting antidepressants, depression, dissociation, ketamine side effects, glutamate receptor antagonism, antidepressant targets
- MeSH terms
- Animals, Antidepressive Agents, Behavior, Animal, Hippocampus, Ketamine, Male, Xenopus laevis, Receptors, N-Methyl-D-Aspartate, N-Methylaspartate, Pyramidal Cells, Excitatory Postsynaptic Potentials, Inhibitory Concentration 50, Protein Subunits, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.